EUVIMEDEUVIMED entdecken
Crossref

Top advances of the year: Neoadjuvant therapy in pancreatic cancer

Jorge I Portuondo, Matthew H G Katz iD

Cancer · 01.05.2026 · 132 (9)

DOI: 10.1002/cncr.70431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 02.05.2026. Verfasst von Jorge I Portuondo und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent phase 3 trials have generated clinically actionable data that help define neoadjuvant therapy for localized pancreatic ductal adenocarcinoma, while exposing the limitations of anatomic patient selection. Emerging evidence signals that the field is poised to transition toward biology‐driven, response‐adaptive frameworks.

Schlagwörter

Stichwörter der Autor:innen

chemoradiotherapychemotherapyneoadjuvant therapypancreas cancerprecision oncology

Autor:innen und Institutionen

  • The Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Matthew H G Katz

Zitieren

APA

Portuondo, J. I., & Katz, M. H. G. (2026). Top advances of the year: Neoadjuvant therapy in pancreatic cancer. Cancer, 132(9). https://doi.org/10.1002/cncr.70431

Vancouver

Portuondo JI, Katz MHG. Top advances of the year: Neoadjuvant therapy in pancreatic cancer. Cancer. 2026;132(9). doi:10.1002/cncr.70431

BibTeX
@article{Portuondo2026,
  author = {Portuondo, Jorge I and Katz, Matthew H G},
  title = {Top advances of the year: Neoadjuvant therapy in pancreatic cancer},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {9},
  doi = {10.1002/cncr.70431}
}
Kostenlos starten →